Alkermes plc today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International Research Society (SIRS).

New global data analysis from Phesi shows the extent of the impact from the war in Ukraine on clinical development.


Teva Pharmaceutical Industries Ltd. reported solid results for full-year 2021, posting $15.9 billion in revenue including a gain of $4.1 billion from the fourth quarter. The company recently settled an opioid-related case in Texas and is preparing to pay as much as $3.6 billion in cash and medicine to settle the lawsuits filed against Teva.

Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia. 

U.K.-based Monument Therapeutics hopes to overcome limitations of treatments for schizophrenia drugs with a study of the company’s proprietary non-invasive biomarker for cognitive impairment.

The U.S. Food and Drug Administration greenlit Janssen’s long-acting, twice-per-year schizophrenia drug Invega Hafyera (paliperidone palmitate six-month).

Alkermes Plc said on June 1 the U.S. Food and Drug Administration approved the company’s Lybalvi for the treatment of schizophrenia and bipolar I disorder.

Several biopharmaceutical companies submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration in recent weeks, covering treatment indications ranging from an opioid overdose to bipolar disorder and rare disease.

Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.

The U.S. Food and Drug Administration issued a Complete Response Letter for Alkermes’ New Drug Application for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and bipolar 1 disorder, and a CRL for Adamis Pharmaceuticals’ NDA for the high-dose naloxone injection product ZIMHI for the treatment of opioid overdose.